Expect Innovation, Excellence at ASCO Research Community Forum 2018 Annual Meeting

Expect Innovation, Excellence at ASCO Research Community Forum 2018 Annual Meeting

Guest Commentary

May 25, 2018

Dr. Edward S. KimBy Edward S. Kim, MD​

This year’s ASCO Research Community Forum (RCF) 2018 Annual Meeting will not be one to miss! Though still a few months away, I am thrilled to share the work that is already underway to bring the research community together for 2 days of learning and collaboration.

During my term as chair of the ASCO Research Community Forum Council, I am specifically eager to share best practices and develop innovative solutions with my peers and multiple stakeholders to facilitate clinical trial participation and accrual.

The theme for the 2018 meeting is Innovative Solutions. Best Practices. Excellence in Cancer Research. This year’s meeting will take place on September 23-24, 2018, at ASCO’s headquarters in the Washington, DC, metropolitan area. Physician investigators and research staff from across the country are invited to join us to discuss best practices and develop solutions to challenges affecting the cancer research community.

Established in 2010, the RCF was created as a solution-oriented venue for research sites and is a go-to resource for the oncology research community. The Forum Annual Meeting brings together established thought leaders with aspiring community research teams; individual practices, community hospitals, and academic research networks, among others. Each year, attendees hear from presenters and panelists representing a variety of stakeholders and come together to identify actionable solutions that ultimately enhance patient enrollment in cancer clinical trials.

Day 1 of the meeting will feature a training workshop on the business of clinical trials, which will provide practical strategies to optimize clinical trial sites and implement best practices. Additionally, a networking event will provide an excellent opportunity for participants to connect with colleagues representing a wide range of research programs from across the United States.

Day 2 features general sessions and multi-stakeholder panel discussions, presentations, and several breakout discussions on a variety of topics impacting cancer research sites including improving efficiencies, reducing site burden and expediting clinical trial start-up, impending regulatory changes, considerations for new and emerging therapies, and increasing trial awareness and accrual. Attendees will also hear from ASCO President-Elect Howard A. “Skip” Burris III, MD, FACP, FASCO, who will give the keynote address.

Those who attend also have the opportunity to receive continuing education credits through the meeting. Research staff who attend this year’s meeting as a group can receive a discount and should contact the ASCO Research Community Forum for more details.

Space is limited—register for this year’s meeting today!

I also encourage those who aren’t familiar with the work of the Forum to visit the ASCO Research Community Forum webpage to learn more and view the many free tools and resources for research sites available year-round, including the ASCO Research Program Quality Assessment ToolASCO Clinical Trial Workload Assessment Tool,  Clinical Trial Resource Library, and the ASCO Insurance Coverage of Clinical Trials toolkit.

Dr. Kim serves as chair of the ASCO Research Community Forum Council and chair of the Department of Solid Tumor Oncology and Investigational Therapeutics at Levine Cancer Institute in Charlotte, NC.

Disclaimer: 

The ideas and opinions expressed on the ASCO Connection Blogs do not necessarily reflect those of ASCO. None of the information posted on ASCOconnection.org is intended as medical, legal, or business advice, or advice about reimbursement for health care services. The mention of any product, service, company, therapy or physician practice on ASCOconnection.org does not constitute an endorsement of any kind by ASCO. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in, posted on, or linked to this site, or any errors or omissions.

Advertisement
Back to Top